Affimed Net Income 2014-2021 | AFMD

Affimed net income from 2014 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Affimed Annual Net Income
(Millions of US $)
2020 $-47
2019 $-36
2018 $-23
2017 $-34
2016 $-36
2015 $-22
2014 $-0
2013 $-35
2012 $-18
Affimed Quarterly Net Income
(Millions of US $)
2021-06-30 $-23
2021-03-31 $2
2020-12-31 $-18
2020-09-30 $-7
2020-06-30 $-13
2020-03-31 $-9
2019-12-31 $-15
2019-09-30 $-12
2019-06-30 $-12
2019-03-31 $2
2018-12-31 $11
2018-09-30 $-14
2018-06-30 $-10
2018-03-31 $-10
2017-12-31 $-8
2017-09-30 $-10
2017-06-30 $-9
2017-03-31 $-8
2016-12-31 $-6
2016-09-30 $-11
2016-06-30 $-9
2016-03-31 $-9
2015-12-31 $-7
2015-09-30 $-8
2015-06-30 $-6
2015-03-31 $-2
2014-12-31 $-6
2014-09-30 $9
2014-06-30 $18
2014-03-31 $-21
2013-09-30 $-15
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.589B $0.032B
Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76